close

Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions. It is conducting an international Phase III registration study of its lead product candidate, retaspimycin hydrochloride (IPI-504), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90), in patients with refractory gastrointestinal stromal tumors; and a Phase I/II clinical trial in patients with advanced non-small cell lung cancer. The company's developing products include IPI-504 in combination with Taxotere in Phase Ib clinical trial for patients with solid tumors; IPI-493, an orally-delivered inhibitor of Hsp90 for patients with advanced solid tumors in Phase I clinical trial; and IPI-926, a hedgehog pathway inhibitor for patients with advanced and/or metastatic solid tumors in Phase I clinical trial. Further, the company has a discovery program focusing on fatty acid amide hydrolase, an enzyme that degrades anandamide and is targeted for neuropathic pain; and developing compounds that target Bcl-2, or Bcl-2 and Bcl-xL anti-apoptotic proteins. Infinity Pharmaceuticals has strategic alliance agreements with Mundipharma International Corporation Limited and Purdue Pharmaceutical Products L.P. to develop and commercialize pharmaceutical products; and a product development and commercialization agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway. The company is headquartered in Cambridge, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	10.08
Volume	186926
Volume Avg	143094
52 Week High	10.42
52 Week Low	5.23
PE	N/A
PE (group average)	N/A
EPS Year	-1.51
EPS change Q/Q	-83.02%
EPS change Q/Q Yr ago	-70.97%
EPS change Q/Q next Q est	-73.53%
EPS change Y/Y	-17.58%
REV change Q/Q	97.1%
REV change Q/Q Yr ago	66.87%
EPS next Q est	-0.34
EPS next Y est	-1.46
Divident Annual	0.00
Dividend Yield	0%